Table 4.

Baseline characteristics of the salvianolate injection group and the alprostadil injection group in the surgery sample.

Variable	Total		Salvianolate injection group		Alprostadil injection group		Z/χ2	P
	(N = 180)		(N = 90)		(N = 90)
	N	%	N	%	N	%
Age, P50 (P25-P75)	66 (59–72)		64 (59–72)		68 (59–73)		0.59	0.5535
Gender							0.37	0.5428
Male	108	60.0	52	57.8	56	62.2
Female	72	40.0	38	42.2	34	37.8
Level of medical institutions							0.03	0.9852
Tertiary hospital	133	73.9	66	73.3	67	74.4
Secondary hospital	45	25.0	23	25.6	22	24.4
Primary hospital	2	1.1	1	1.1	1	1.1
Region							2.67	0.2636
Eastern region	108	60.0	54	60.0	54	60.0
Central region	54	30.0	30	33.3	24	26.7
Western region	18	10.0	6	6.7	12	13.3
Comorbidity							0.02	0.8793
High blood pressure	73	40.6	36	40.0	37	41.1
Heart failure	21	11.7	10	11.1	11	12.2	0.05	0.8164
Atrial fibrillation	2	1.1	1	1.1	1	1.1	0.00	1.0000
Heart valve disease	1	0.6	0	0.0	1	1.1	1.01	0.3160
Stroke	16	8.9	8	8.9	8	8.9	0.00	1.0000
Pulmonary embolism	0	0.0	0	0.0	0	0.0	\
COPD	0	0.0	0	0.0	0	0.0	\
Chronic nephrosis	5	2.8	2	2.2	3	3.3	0.21	0.6501
Diabetes	72	40.0	36	40.0	36	40.0	0.00	1.0000
Drug combination
Beta blockers	112	62.2	53	58.9	59	65.6	0.85	0.3563
Nitrate esters	174	96.7	84	93.3	90	100.0	6.21	0.0127
ACEI or ARB	96	53.3	45	50.0	51	56.7	0.80	0.3700
Calcium antagonist	64	35.6	27	30.0	37	41.1	2.42	0.1194
Antiplatelet/thrombolytic/anticoagulant	166	92.2	81	90.0	85	94.4	1.24	0.2656
Lipid regulating agents	160	88.9	82	91.1	78	86.7	0.90	0.3428
Related surgery of CHD	41	22.8	23	25.6	18	20.0	0.79	0.3742